Intrapleural treatment in patients with non-small cell lung cancer with malignant pleural effusions in the real world.

ABSTRACT:

Background

The aim of the study was to assess the efficacy and side-effects of intrapleural treatment in non-small cell lung cancer (NSCLC) patients with malignant pleural effusions (MPEs).

Methods

The medical records of NSCLC patients with MPEs diagnosed in four Chinese hospitals from October 2014 to December 2019 were searched. The Kaplan-Meier method is used to calculate median overall survival (MOS) and subgroup analyses are done.

Results

A total of 285 patients were evaluated; 81.1% of patients received intrapleural treatment, and no patients received talc pleurodesis. MOS of the whole cohort was 21 months. Patients were divided into three groups: erythromycin group (EG; intrapleural treatment with drugs and erythromycin); intrathoracic treatment group (ITG; intr

SUBMITTER: Pan P 

PROVIDER: S-EPMC8671907 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature